نتائج البحث

Prolonged 14-day continuous infusion of high-dose ifosfamide for patients with relapsed and refractory high-grade osteosarcoma: a retrospective multicentre cohort study.

• Authors : Tirtei, Elisa^1,2 (AUTHOR); Campello, Anna¹ (AUTHOR) ; Sciannameo, Veronica³ (AUTHOR)

• Source: BMC Cancer. 6/19/2024, Vol. 24 Issue 1, p1-12. 12p.

تفاصيل العنوان

A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma

• Source: A Phase IB, Open-Label, Multicenter, Single Arm Study Evaluating the Preliminary Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus

تفاصيل العنوان

A Rare Case of Methemoglobinemia after Ifosfamide Infusion in a 3-Year-Old Patient Treated for T-ALL.

• Authors : Suprunowicz, Maria¹ (AUTHOR); Marcinkiewicz, Katarzyna¹ (AUTHOR); Leszczyńska, Elżbieta¹ (AUTHOR)

Subjects: *IFOSFAMIDE; *METHEMOGLOBINEMIA; *BLOOD transfusion

• Source: International Journal of Molecular Sciences. Apr2024, Vol. 25 Issue 7, p3789. 9p.

تفاصيل العنوان

Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL

• Authors : National Cancer Institute (NCI)

• Source: A Phase II Trial of Response-Adapted Second-Line Therapy for Hodgkin Lymphoma Using Anti-PD-1 Antibody Nivolumab ? ICE Chemotherapy as a Bridge to Autologous Hematopoietic Cell Transplant (NICE

تفاصيل العنوان

Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate in neoadjuvant treatment of resectable osteosarcoma: A prospective, single-arm, exploratory phase II trial.

• Authors : Tang Q; Department of Musculoskeletal Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.

Subjects: Osteosarcoma*/Osteosarcoma*/Osteosarcoma*/drug therapy ; Osteosarcoma*/Osteosarcoma*/Osteosarcoma*/mortality ; Osteosarcoma*/Osteosarcoma*/Osteosarcoma*/therapy

• Source: Cancer medicine [Cancer Med] 2024 Sep; Vol. 13 (18), pp. e70206.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (BV-ICE)

• Authors : National Cancer Institute (NCI); Seagen Inc.; Ajay Gopal, Professor, Department of Medicine, Division of Oncology

• Source: A Phase I/II Trial of Brentuximab Vedotin (BV), Ifosfamide (I), Carboplatin (C), and Etoposide (E) for Patients With Relapsed or Refractory Hodgkin Lymphoma (BV-ICE)

تفاصيل العنوان

Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma

• Authors : National Cancer Institute (NCI); Amgen

• Source: Phase I/Ib Study of Carfilzomib Plus Rituximab Plus Ifosfamide Plus Carboplatin Plus Etoposide (C-R-ICE) in Patients With Relapsed/Refractory Diffuse Large B-Cell

تفاصيل العنوان

Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

• Authors : National Cancer Institute (NCI)

• Source: A Phase 2 Study of Polatuzumab Vedotin With Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for Relapsed/Refractory Diffuse

تفاصيل العنوان

A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma

• Authors : Merck Sharp & Dohme LLC

• Source: A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination With Ifosfamide and Etoposide Versus

تفاصيل العنوان

Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors

• Authors : University of Southern California; Mayo Clinic; University of Pittsburgh

• Source: Randomized Phase II Trial of Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated

تفاصيل العنوان